Open AccessTargeting PKCι-PAK1 in EGFR-mutation positive non-small cell lung cancer
Author(s) -
Masaoki Ito,
Carles Codony-Servat,
Niki Karachaliou,
Rafael Rosell
Publication year - 2019
Publication title -
translational lung cancer research
Language(s) - Uncategorized
Resource type - Journals
eISSN - 2226-4477
pISSN - 2218-6751
DOI - 10.21037/tlcr.2019.08.25
Subject(s) - auranofin , cancer research , epidermal growth factor receptor , medicine , lung cancer , protein kinase b , tyrosine kinase , signal transduction , cancer , biology , oncology , immunology , receptor , microbiology and biotechnology , rheumatoid arthritis
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) induce significant responses in EGFR-mutation positive non-small cell lung cancer (NSCLC). However, universal progression is observed.